| CPC C07H 21/02 (2013.01) [C12N 9/1247 (2013.01); C12P 19/34 (2013.01); C12Y 207/07006 (2013.01); A61K 31/7115 (2013.01); A61K 31/712 (2013.01); A61K 31/7125 (2013.01)] | 6 Claims |

|
1. An in vitro-transcribed (IVY) mRNA sequence initiator comprising a compound of formula (II) or a salt or solvate thereof:
![]() Wherein
B1 is
![]() each B2, B3, and Bn is independently a natural, a modified, or an unnatural nucleobase;
each Z′ and Z″ is independently is hydrogen, fluorine, —OH, —SH, —CH3, —CH2CH3, —OCH3, —NH(CH3), —NH3, —NH(C(═O)CH3), or —SCH3;
Z′″ is hydrogen, fluorine, —CH3, —CH2CH3, —OCH3, or —OCH2CH3;
each Z1 and Z2 is independently hydrogen, fluorine, —OH, —SH, —CH3, —CH2CH3, —OCH3, —SCH3, —OCH2CH3, —NH2, NHCH3, or NHC(═O)CH3;
each Z3, Z4, and Zn is independently hydrogen, fluorine, —OH, —CH3, —CH2CH3, —OCH3, —NH2, —NHCH3, —NH(C(═O)CH3), —OCH2CH3, —OCH2OCH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3, or —OCH2CH2OCH3;
each Q1 and Q4 is independently —CH═CH—, —CH2—, —CH2O—, —CH2S—, —CH2CH2—, —CH2CF2—, —CH2NH2—, —CH2NH(CH3)—, or —CH2N(C(═O)CH3);
each Q2 and Q3 is independently —O—, —S—, —CH2—, —CF2—, —NH—, —N(CH3)—, or —N(C(═O)CH3)—;
each X1, X2, X3, X4, and X5 is independently —OH, —SH, —O−, —S−, —NH2, —NHCH3, —NH(C(═O)CH3), —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2—OCH3 or —OCH2CH3;
each Y1, Y2, Y3, Y4, and Y5 is independently ═O, ═S, ═NH, or ═NCH3;
each A, A1, and A2 is independently —O—, —S—, —CH2—, —NH—, —N(CH3)— or —N(C(═O)CH3); and
p=0, 1, 2, 3, 4, 5 or 6.
|